We described here a modification of the hCG beta-subunit radioimmunoassay that circumvents this non-specific interference and allows the detection and quantification of choriogonadotropmn in urine. Immunoprecipitability was maximum when the specific activity of Na125I was less than 300 Ci/liter.
Materials and Methods

Reagents
Radioimmunoassay Procedures
Add reagents to 12 X 75 mm glass tubes in the following sequence: 100 l of unknown urine sample or standard dissolved in 100 l of pooled urine from men, 200 il of unIlabeled choriogonadotropin (10 000 cpm), 200 zl of suitably diluted antiserum to hCG-beta subunit, 100 ,zl of 0.1 mol/liter (ethylenedinitrilo)tetraacetic acid in distilled water, pH 7.6, and 400 tl of buffer. Vortex mix the reagents and equilibrate for 16 h at 4 #{176}C; then add goat anti-rabbit serum in a quantity sufficient to produce a bound/total ratio of 33% in the tubes without added hCG. After a further 6-h equilibration, centrifuge the tubes, discard the supernate, and count the radioactivity in the precipitate in a gamma counter.
We performed the rapid modification of the hCG-betasubunit radioimmunoassay in which dioxane is used in place of goat anti-rabbit serum, by the technique previously described (4), with all standards dissolved in 100 il of pooled urine from men.
Samples
Simultaneously collected untimed specimens of urine and blood were obtained from 312 menstruating women, ages 21-39, 71 women who were one to six days postpartum, 44 men, and five postmenopausal women. Sixteen untimed urine specimens were also #{244}ollected serially from postmenopausal women in order to examine the variables of urine concentration, time of collection, and possible interference in the radioimmunoassays by the high hLH concentrations present in the urine of these women.
Serum was frozen at -20 #{176}C until assayed. The urine samples were apportioned and frozen at -20 #{176}C. At the time of assay the urines were thawed to room temperature, mixed, and any sediment present was allowed to settle before the supernatant fluid was assayed.
Statistical
Treatment of Data
We used a modification of the statistical methods of Rodbard and Frazier for dose interpolation and determination of inter-assay and intra-assay coefficients of variation (6) . Student's t -test, linear regression analysis,
and Pearson product-moment correlations were done.
Results
Assay Validation Figure 1 illustrates the effect of adding 100-, 200-, 300-, and 500-id samples of urine from a normal menstruating woman to the standards used to prepare the standard curve in the double antibody hCG beta-subunit radioimmunoassay. The 100-izl sample curve was nearly identical to that obtained with buffer, but addition of the larger volumes of urine (300 and 500 1d) resulted in deviation from parallelism and a decrease in the sensitivity.
Urine from men gave similar results, although not as marked. Therefore, 100 l of urine from men was used in tubes for the standard curves, and all dilutions of unknown urines were made in pooled urine from men to give a final urine volume of 100 iil. Serial dilutions of urine from 
Correlation of Serum and Urinary hCG Concentrations
Simultaneously collected blood and urine samples were obtained from 71 postpartum women and 47 women early in the first trimester of their pregnancy. The hCG concentrations in these samples, assayed in the respective double-antibody hCG beta-subunit radioimmunoassays, were highly correlated (r = 0.76,P <0.001) (Figure 3) .
The serum and urine samples obtained from the 275 menstruating women were also tested in both assays. No immunoreactive hCG was detected in any of these serum samples. 
Precision and Reproducibility
The between-assay coefficient of variation was 11.8% and After 5, 10, and 20 ng of purified hCG was added to concanavalin A-stripped urine, 96, 105, and 101%, respectively, could be analytically accounted for.
Stability of hCG in Urine
To determine the stability of the hCG concentrations in the urine samples, we collected urine from five pregnant women and divided it into portions, which were either frozen at -20 #{176}C without delay, allowed to set at room temperature for one to seven days before freezing, or refrigerated at 4 #{176}C for one to seven days before freezing. Another portion of each sample was repeatedly frozen and thawed, as many as nine times. We determined immunoreactive hCG in all portions concurrently, to eliminate between-assay variation. hCG activity significantly decreased in the samples of urine maintained at room temperature or at 4 #{176}C as compared to those frozen immediately (P <0.01). Repeated freezing and thawing had no effect on the concentration of immunoreactive hCG.
Comparison of Double-Antibody and Dioxane hCG Beta-Subunit Radioimmunoassays Urine samples with various hCG concentrations from 26 pregnant women, and from eight postmenopausal women and 25 menstruating women were analyzed for hCG with both the double-antibody and the rapid dioxane hCG beta-subunit radioimmunoassay. The resulting values showed no significant difference between assays (r = 0.96, P <0.001, n = 55). Figure   4 depicts the comparison for the 26 pregnant women.
Discussion
Our studies indicate that the hCG beta-subunit radioimmunoassay, as modified, can specifically measure hCG in the urine of pregnant women when the hormone is present in concentrations exceeding 40 mt. units/liter. At these concentrations the high concentrations of hLH in the urine of postmenopausal women and in the urine of women with mid-cycle peaks in hLH excretion do not interfere. Neither the urine volume nor time of voiding had an substantial relation to urinary hCG concentration. These results are compatible with those of other investigators who demonstrated that measurements of pituitary gonadotropins in either single first (morning) voidings or a 3-h urine sample validly reflect total 24-h excretion of the hormone in urine (7, 8) . Our results also demonstrate the close correlation between serum and urinary hCG, again indicating that measurement of hCG concentrations in casual (i.e., not strictly timed) urine samples provides a reliable means of indirectly monitoring serum hCG concentrations.
If one considers our previously published data on the time course of the appearance of immunoreactive hCG in the serum after fertilization (9), the minimum sensitivity of 44)hit. units of hCG per liter of urine would allow a diagnosis of pregnancy as early as 10 days after conception or 25 days after the last menstrual period, considerably more sensitive than the urinary slide or tube hemagglutination or latex-agglutination pregnancy tests, which require that 750 to 3500 int. units hCG be present per liter of urine before the reaction is positive (2). The radioreceptor assay described by Saxena et al. (10) is quite sensitive to small amounts of hCG, but the receptor does not discriminate between hCG and hLH and therefore would have to exceed 78 ig of hCG per liter before one could reliably state that hCG wasdetected in an untimed urine sample (10) .
Because the radioreceptor assay generally measures two-to threefold more hormone in the same specimen than does the hCG beta-subunit radioimmunoassay, this would indicate that the hCG concentration in the urine must be between 312 and 468 mt.units/liter in terms of immunological activity before the radioreceptor assay would become specific for hCG.
The virtually identical values obtained with the doubleantibody and rapid dioxane radioimmunoassays indicates that as little as 40 int. units of hCG per liter of urine can be reliably measured in an untimed sample of urine within 3 h. The relative ease of collection and the decreased sample preparation time are some of the advantages of measuring hCG in the urine rather than in the serum. Because the currently available commercial slide and tube pregnancy tests are relatively insensitive and are unable to detect hCG in about half of patients with ectopic pregnancies (4), the use of this assay may provide a rapid confirmation of pregnancy. Similarly, this test could be used to detect the low amounts of hCG excreted by a large proportion of patients with germ cell tumors of the testes and in monitoring the therapy of gestational trophoblastic disease (11) .
